contains policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy. The main novelties of the 2016 WHO guidelines are: a shorter MDR-TB treatment regimen is recommended under specific conditions; medicines used in the design of conventional MDR-TB treatment regimens are now reclassified to reflect updates in the evidence on their effectiveness and safety; specific recommendations are made on the treatment of children with rifampicin-resistant or MDR-TB based on a first-ever individual patient data meta-analysis; recommendations on the role of surgery in MDR-TB case management are included.